City: 40225 Düsseldorf
Projects: LiSyM Pillar II: Chronic Liver Disease Progression (LiSyM-DP), LiSyM Pillar III: Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF), LiSyM network, LiSyM-Krebs Partnering, LiSyM-Krebs
Roles: Project Coordinator
Tools: Milliplex analysis, qPCR, Molecular Biology, Laser scan microscopy, Immunohistochemistry, Cell and tissue culture, confocal microscopy, Mouse surgery, RNA analysis, rtPCR, Cytometry and fluorescent microscopy, Mouse experiments in vivo, Isolation of primary cells (hepatocytes and non-parenchymal cells)
I received my diploma in biology in 2001 from the Heinrich-Heine-University in Duesseldorf and the Dr. rer. nat. (Ph.D.) degree in 2006 from the University of Hohenheim in Germany. The practical part of my Ph.D. thesis had been realized at the clinic for gastroenterology, hepatology and infectiology at the university hospital in Duesseldorf. After my Ph.D. I focussed my studies on MAP-kinase-regulated cytokine/chemokine expression in response to bacterial or viral pathogens with a main issue on
In one in five people with NAFLD, the functioning liver cells, the hepatocytes, are replaced by connective tissue. Eventually this fibrosis becomes irreversible. In this state the liver is like a ‘scar that never heals’. Through it, the liver loses many of its vital functions.
LiSyM-Pillar II wants to know more about which factors promote fibrosis and the conditions under which fibrosis becomes irreversible How can fibrosis be diagnosed as early as possible? Researchers in the pillar are also
This generic project is intended to be a forum for all LiSyM partner and external stakeholders interested in participating in the BMBF initiative LiSyM-Krebs.
Organisms: Not specified
In chronic diseases, at some point the liver can suddenly stop functioning. This is called acute-on-chronic liver failure, or ACLF. This is the leading cause of death in liver patients and is often provoked by the use of transcription or freely available drugs or alcohol abuse. For this condition we need an effective treatment quickly.
LiSyM-Pillar III researches the factors that contribute significantly to ACLF. What exactly happens then? Are there any early signs that would enable ACLF to be